Help protect against pneumococcal pneumonia

1. Australian Government, Department of Health. Health Topics: Pneumococcal Disease. https://www.health.gov.au/health-topics/pneumococcal-disease [accessed February 2020]. 2. Menzies R et al. Vaccine myopia: adult vaccination also needs attention. Med J Aust. 2017;206(6):2.e1. 3. Earle K et al. Burden of pneumococcal disease in adults aged 65 years and older: an Australian perspective. Pneumonia (Nathan). 2016;8:9. 4. Australian Government Department of Health. The Australian Immunisation Program: Older Australians. http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/older-australians [accessed February 2020]. 5. Health Stats NSW Influenza and pneumococcal disease immunisation by age, trend. 6. Family Medicine Research Centre. University of Sydney. SAND abstract No. 223 from the BEACH program. Sydney: FMRC University of Sydney, 2014. http://sydney.edu.au/medicine/fmrc/publications/sand-abstracts/223-pneumococcal_vaccination.pdf [accessed February 2020]. 7. Australian Government, Department of Health. Pharmaceutical Benefits Scheme. http://www.pbs.gov.au/medicine/item/10210J-1903E [accessed February 2020].

Seqirus (Australia) Pty Ltd. 63 Poplar Road, Parkville, VIC 3052. ABN 66 120 398 067. Medical Information: 1800 642 865. Pneumovax^® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. Seqirus™ is a trademark of Seqirus UK Limited or its affiliates.

Date of preparation: March 2020. SEQ/PNEU/1218/012(1) 
Privacy statement: Information regarding Seqirus’ handling of personal information is available at www.seqirus.com.au/privacy. You are receiving this email because you registered your interest in the Community Immunity website.